Fumitremorgin C

Bioviotica
Product Code: BVT-0189
Supplier: Bioviotica

CodeSizePrice
BVT-0189-C250250 ug£100.00
Quantity:
BVT-0189-M0011 mg£175.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
FTC; Tryptoquivaline
Appearance:
White to light brown powder.
CAS:
118974-02-0
Class:
6.1
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS06
Handling Advice:
Protect from light when in solution.
Hazards:
H301, H302, H311, H319
InChi:
InChI=1S/C22H25N3O3/c1-12(2)9-18-20-15(14-7-6-13(28-3)10-16(14)23-20)11-19-21(26)24-8-4-5-17(24)22(27)25(18)19/h6-7,9-10,17-19,23H,4-5,8,11H2,1-3H3/t17-,18-,19-/m0/s1
InChiKey:
DBEYVIGIPJSTOR-FHWLQOOXSA-N
Long Description:
Chemical. CAS: 118974-02-0. Formula: C22H25N3O3. MW: 379.5. Isolated from Aspergillus fumigatus. Mycotoxin. Cytotoxic. Tremorgenic. Potent and specific inhibitor of the breast cancer resistance protein (BCRP; ABCG2). Reverses multidrug resistance mediated by BCRP and increases cytotoxicity of several anticancer agents in vitro.
MDL:
MFCD08702652
Molecular Formula:
C22H25N3O3
Molecular Weight:
379.5
Other data:
A concentration of 1mg/ml is recommended for stock solutions.
Package Type:
Plastic Vial
PG:
III
Precautions:
P280, P301, P310, P301, P312, P302, P352, P405
Product Description:
Mycotoxin. Cytotoxic. Tremorgenic. Potent and specific inhibitor of the breast cancer resistance protein (BCRP; ABCG2). Reverses multidrug resistance mediated by BCRP and increases cytotoxicity of several anticancer agents in vitro.
Purity:
>98% (HPLC)
Signal word:
Danger
SMILES:
[H][C@@]12CCCN1C(=O)[C@]1([H])CC3=C(NC4=C3C=CC(OC)=C4)[C@H](C=C(C)C)N1C2=O
Solubility Chemicals:
Soluble in DMSO, methanol, acetone, DMF or chloroform.
Source / Host:
Isolated from Aspergillus fumigatus.
Transportation:
Excepted Quantity
UN Nummer:
UN 3462
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C. After reconstitution protect from light at -20°C.

References

Mycotoxins produced by Aspergillus fumigatus species isolated from molded silage: R.J. Cole, et al.; J. Agric. Food Chem. 25, 826 (1977) | Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties: C.B. Cui, et al.; J. Antibiot. 49, 527 (1996) | Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin: S.K. Rabindran, et al.; Cancer Res. 58, 5850 (1998) | Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.: S.K. Rabindran, et al.; Cancer Res. 60, 47 (2000) | Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.:Ozvegy, et al.; J. Biol. Chem. 277, 47980 (2002) | The role of breast cancer resistance protein in acute lymphoblastic leukemia: S.L. Plasschaert, et al.; Clin. Cancer Res. 9, 5171 (2003) | Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors: T.S. Garimella, et al.; Cancer Chemother. Pharmacol. 55, 101 (2005) | Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes: S. Hauswald, et al.; Clin. Cancer Res. 15, 3705 (2009) | Specific inhibitors of the breast cancer resistance protein (BCRP): A. Pick, et al.; ChemMedChem 5, 1498 (2010) | Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C: L. Gonzales-Lobato, et al.; Eur. J. Pharmacol. 644, 41 (2010) | Cytotoxic compounds from the marine-derived fungus Aspergillus sp. recovered from the sediments of the Brazilian coast: N. N. Saraiva, et al.; Nat. Prod. Res. 29, 1545 (2014) | Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells: H.L. Huang, et al.; Oncol. Lett. 9, 1287 (2015)

Related Products

Product NameProduct CodeSupplier 
AverantinBVT-0169Bioviotica Summary Details
SterigmatocystinBVT-0171Bioviotica Summary Details